The American College of Cardiology (ACC), Heart Failure Society of America (HFSA), Heart Rhythm Society (HRS) and Society for Cardiovascular Angiography and Interventions (SCAI) have announced a partnership to develop new modules to help subspecialty cardiologists—interventional cardiologists, electrophysiologists, and heart failure specialists—to potentially meet collaborative maintenance pathway requirements equivalent to satisfying the American Board of Internal Medicine (ABIM)’s current 10-year merit of certification (MOC) examination.
A new study indicates that coronary angiography, with or without percutaneous coronary intervention (PCI), is feasible in patients who have undergone transcatheter aortic valve implantation (TAVI) with a self-expanding valve (CoreValve, Medtronic).
The US FDA has granted 510(k) clearance to Creavo Medical Technologies for its portable scanning device, Vitalscan. A press release reports that the move opens the US market for the device and demonstrates an increasing industry focus on the global challenges hospitals face when it comes to triaging chest pain patients.
Garen Wintemute (Violence Prevention Program, University of California Davis, USA), in an editorial in the Annals of Internal Medicine, has called for physicians to make a public commitment to talk to their patients about firearms, counsel them on safe firearm behaviours, and take further action when an imminent hazard is present.
Vivasure Medical has announced the successful enrolment of the first patient in the Frontier IV clinical study, a non-randomised multicentre international trial, designed to expand the indications of its proprietary PerQseal large arteriotomy closure technology. The patient was enrolled by Peter Crean (Blackrock Clinic, Dublin, Ireland).
The Geoffrey O. Hartzler Master Clinical Operator Award will be presented to Alec Vahanian (Cardiology Department, University Paris Diderot, Bichat Hospital, AP-HP, Paris, France) at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Denver, Colorado). The award is given each year to a physician who has advanced the field of interventional cardiovascular medicine through technical excellence and innovation.
A first-in-man, feasibility study of the use of the RenalGuard system in patients undergoing coronary artery bypass grafting (CABG) shows the potential of RenalGuard therapy to safely reduce the incidence of acute kidney injury in the cardiac surgery setting. The 10-patient pilot study was published online in the journal Open Heart.
Pamela B Morris has been selected as the next vice chair of the American College of Cardiology (ACC) annual scientific session. She will serve as vice chair for ACC.19 and ACC.20, and will transition to chair for ACC. 21 and ACC.22. According to a press release, ACC established the role of vice chair in 2014 to ensure consistency and continual improvement of the ACC’s flagship meeting.
Biotronik has announced the start of enrolment in a coronary stent trial aiming at assessing the safety and clinical performance of a new coronary stent (Biovtiesse) in de novo coronary artery lesions.
At CSI UCSF Congress, Achille Gaspardone (Hospital of Sant’Eugenio, Rome, Italy) presented a comprehensive report on closure of patent foramen ovale (PFO) and related atrial septal defect using the NobleStitch EL suture based closure system. The data was collected from 10 centres throughout Italy and one centre in Sweden from January 2016 through August 2017, and was gathered from more than 190 patients, from procedures performed by 14 interventional cardiologists.
Vascular Graft Solutions is hosting a symposium on the future of coronary artery bypass grafting (CABG) at the European Association for Cardio-Thoracic Surgery (EACTS) annual meeting (7–11 October, Vienna, Austria). The symposium—entitled “CABG: Back to the Future”—will take place at 12.45pm on Monday 9th October in PM Room 0.11/0.12 and will discusss the venous external support (VEST) device.
Fahad Alqahtani (Division of Cardiology, West Virginia University Heart & Vascular Institute, Morgantown, USA) and others report in Catheterization and Cardiovascular Interventions that there are no significant differences in utilisation rates, in-hospital outcomes, and cost between African American and Caucasian patients undergoing transcatheter aortic valve implantation (TAVI).
BioVentrix has announced that the first patient has been enrolled in the US arm of the ALIVE pivotal clinical trial. The trial is designed to demonstrate the safety and effectiveness of the Revivent TC TransCatheter Ventricular Enhancement System; a hybrid closed-chest procedure to treat patients suffering from heart failure symptoms related to cardiomyopathy. BioVentrix previously received investigational device exemption (IDE) approval for the study from the US FDA.
The first patient was treated in the CONTROL hypertension (HTN)-2 clinical study, the Rox Medical’s pivotal study to evaluate the safety and effectiveness of the Rox Coupler used to create an arteriovenous anastomosis in the iliac vessels, in patients with high blood pressure.
A study published in the Journal of the American College of Cardiology indicates that people who do not eat breakfast have an increased risk of developing atherosclerosis. While previous studies have linked skipping breakfast to coronary heart disease risk, a press release reports, this is the first study to evaluate the association between breakfast and the presence of subclinical atherosclerosis.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos